A neglected Ebola variant is spreading in Central Africa, and the world is scrambling to build a vaccine it should have made years ago.
Picture a clock on a wall in Kinshasa. Every tick, Dr Richard Hatchett reminds us, matters. "Every day counts in the race against this deadly disease," the chief executive of the Coalition for Epidemic Preparedness Innovations (CEPI) said on Monday, when his organisation announced $60 million in emergency funding for three vaccine developers. The target is the Bundibugyo strain of Ebola — a variant that, unlike its more famous cousin the Zaire strain, currently has no approved vaccine and no treatment at all.
The outbreak is active in the Democratic Republic of the Congo and has crossed into Uganda, while armed militias in the region have attacked Ebola treatment centres, making it extraordinarily difficult to even begin clinical trials. So who is actually building something? Two candidates are leading the race. The International AIDS Vaccine Initiative (IAVI) is developing the rVSV Bundibugyo vaccine, which uses the same platform as Ervebo — the only approved Ebola vaccine, which works against the Zaire strain.
The World Health Organization has called IAVI's candidate the "most promising" option, though it is not expected to be ready for clinical trials for another seven to nine months.